Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by PWIB123on Apr 25, 2022 9:27pm
154 Views
Post# 34630828

RE:RE:RE:RE:RE:Votes

RE:RE:RE:RE:RE:VotesI just voted 62,053 shares against all directors and against the amendment to the stock option plan.  It looks to me like they have enough stock options to work with for now.  While the stock option plan probably favors company employees over the board, I'm still voting no on the items that immediately benefit the board.  They can work a little harder on the issues discussed here first.  I also voted all my shares in favor of the auditor and the shareholders rights plan.  I actually don't mind the poison pill protection from hostile takeovers.  It seems it gives a little more control to the company and with the crazy volatile and turbulent times we live in along with an already severely depressed share price, I think it makes more sense to have the poison pill in the back pocket just in case.  Many companies still accept takeover offers even with a shareholders rights plan in place.  

I hope the board will begin paying attention to the IR and capital markets issues.  I've at least made my voice heard by way of my vote and tying the negative vote to the board and compensation plans.  

Turns out I had more shares than I remembered in several retirement accounts in addition to my individual brokerage account.  
<< Previous
Bullboard Posts
Next >>